Log In
BCIQ
Print this Print this
 

Hepbarna (shRNAi for hepB)

  Manage Alerts
Collapse Summary General Information
Company Benitec Biopharma Ltd.
DescriptionDNA-directed RNAi (ddRNAi) based therapeutic
Molecular Target
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA: shRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat chronic hepatitis B virus (HBV) infection
Regulatory Designation
PartnerBiomics Biotechnologies Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$4.4M

$1.8M

$2.6M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/09/2015

$4.4M

$1.8M

$2.6M

Get a free BioCentury trial today